Table 2.

Association between receptor activator of the nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) gene polymorphisms and osteoporosis risk.

	OP N (%)	CTRs N (%)	OR (95% CI)	p-Value	Adjusted OR	p-Value *
RANKL gene polymorphism
rs2277438 A/G
AA	122 (73.1)	140 (74.5)	1.0		1.0
AG	42 (25.1)	45 (23.9)	1.0 (0.6–1.6)	0.96	0.9 (0.5–1.6)	0.83
GG	3 (1.8)	3 (1.6)	1.1 (0.2–5.7)	0.88	2.7 (0.4–20.2)	0.32
AG + GG	45 (26.9)	48 (25.5)	1.0 (0.6–1.6)	0.98	1.0 (0.6–1.7)	1.00
A	286 (85.6)	325 (86.4)	1.0		1.0
G	48 (14.4)	51 (13.6)	1.0 (0.7–1.5)	0.98	1.1 (0.6–1.7)	0.81
rs9533156 T/C
TT	73 (42.0)	85 (42.9)	1.0		1.0
TC	76 (43.7)	75 (37.9)	1.2 (0.8–1.8)	0.42	1.2 (0.8–1.9)	0.42
CC	25 (14.4)	38 (19.2)	0.8 (0.4–1.4)	0.41	0.7 (0.4–1.3)	0.28
TC + CC	101 (48.0)	113 (57.1)	1.1 (0.7–1.6)	0.79	1.0 (0.7–1.6)	0.87
T	222 (63.8)	245 (61.9)	1.0		1.0
C	126 (36.2)	151 (38.1)	0.9 (0.7–1.2)	0.63	0.9 (0.6–1.2)	0.48
OPG gene polymorphism
rs2073618 C/G
CC	87 (50.0)	85 (42.9)	1.0		1.0
CG	64 (36.8)	93 (47)	0.7 (0.4–1.0)	0.08	0.6 (0.3–0.97)	0.041
GG	23 (13.2)	20 (10.1)	1.1 (0.6–2.2)	0.75	0.6 (0.2–1.3)	0.17
GG + CG	857 (50.0)	113 (57.1)	0.8 (0.5–1.1)	0.17	0.6 (0.3–0.9)	0.029
C	238 (68.4)	263 (66.4)	1.0		1.0
G	110 (31.6)	133 (33.6)	0.9 (0.7–1.2)	0.57	0.7 (0.5–0.99)	0.044
rs3102735 T/C
TT	113 (79.0)	127 (77.4)	1.0		1.0
TC	27 (18.9)	36 (22.0)	0.8 (0.5–1.4)	0.49	0.7 (0.3–1.3)	0.20
CC	3 (2.1)	1 (0.6)	3.4 (0.4–32.9)	0.29	1.6 (0.1–24.5)	0.72
TC + CC	30 (21.0)	37 (22.6)	0.9 (0.5–1.5)	0.67	0.7 (0.4–1.3)	0.25
T	253 (88.5)	290 (88.4)	1.0		1.0
C	33 (11.5)	38 (11.6)	1.0 (0.6–1.6)	0.92	0.8 (0.4–1.4)	0.34

Note: Data presented as OR (95% CI), * indicates adjusted for age and BMI and menopause (years). p-value < 0.05 considered significant.